ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
6,012.28
-1.46%
US Tech 100
20,615.42
-2.69%
Dow Jones
44,713.58
0.65%
Brent Oil
76.135
-1.36%
Bitcoin
101,013.32
-3.49%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Cocrystal Pharma Inc (COCP)

  7. Cocrystal Pharma Inc (COCP) News

COCP

Cocrystal Pharma (COCP)

Cocrystal Pharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:COCP
DateTimeSourceHeadlineSymbolCompany
01/13/20258:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
01/08/20258:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
01/08/20258:00AMGlobeNewswire Inc.Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral InfectionsNASDAQ:COCPCocrystal Pharma Inc
12/31/20248:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
12/31/20248:00AMGlobeNewswire Inc.Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344NASDAQ:COCPCocrystal Pharma Inc
11/13/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
11/13/20248:30AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COCPCocrystal Pharma Inc
11/13/20248:00AMGlobeNewswire Inc.Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsNASDAQ:COCPCocrystal Pharma Inc
10/31/20249:10AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
10/31/20248:00AMGlobeNewswire Inc.Cocrystal Pharma’s Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season BeginsNASDAQ:COCPCocrystal Pharma Inc
10/11/20244:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COCPCocrystal Pharma Inc
10/11/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COCPCocrystal Pharma Inc
10/11/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COCPCocrystal Pharma Inc
10/11/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COCPCocrystal Pharma Inc
10/10/20245:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
09/26/20248:00AMGlobeNewswire Inc.Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose CohortsNASDAQ:COCPCocrystal Pharma Inc
08/20/20248:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
08/19/20244:05PMGlobeNewswire Inc.Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment ConferencesNASDAQ:COCPCocrystal Pharma Inc
08/14/20248:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
08/14/20248:00AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COCPCocrystal Pharma Inc
08/14/20248:00AMGlobeNewswire Inc.Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsNASDAQ:COCPCocrystal Pharma Inc
07/18/20249:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
07/18/20248:00AMGlobeNewswire Inc.Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease InhibitorNASDAQ:COCPCocrystal Pharma Inc
06/20/20248:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
06/20/20248:00AMGlobeNewswire Inc.New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy CowsNASDAQ:COCPCocrystal Pharma Inc
05/13/20248:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
05/13/20248:00AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COCPCocrystal Pharma Inc
05/13/20248:00AMGlobeNewswire Inc.Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsNASDAQ:COCPCocrystal Pharma Inc
05/07/20244:30PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:COCPCocrystal Pharma Inc
05/01/20248:00AMGlobeNewswire Inc.Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal InfluenzaNASDAQ:COCPCocrystal Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:COCP

Your Recent History

BIT
UV4L4W
UniCredit Bank
BIT
UV8CPY
UniCredit Bank
LSE
0O0E
Bigben Interactive
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads